centerforbiosimilars23h
Long-Term Data Support Use of Eculizumab Biosimilar as Soliris Alternative in PNH
Eculizumab biosimilar Elizaria demonstrates long-term safety and efficacy comparable with the reference product Soliris in ...
centerforbiosimilars1d
Robert Rifkin, MD, FACP
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars1d
Christina Corridon, MPH, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars1d
Mike Gladstone
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars2d
Switching From Ustekinumab to Biosimilar SB17 Maintains Efficacy, Safety in Patients With Psoriasis
Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching and maintained long-term ...
centerforbiosimilars2d
Jeff Baldetti, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars2d
Mayuri Mathuria, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars3d
Eye on Pharma: Teva, Formycon, Celltrion Biosimilar Updates in Global Markets
Three players in the biosimilar space have already sparked hope for the new year, with each having big business or regulatory ...
centerforbiosimilars3d
Skylar Jeremias
Three players in the biosimilar space have already sparked hope for the new year, with each having big business or regulatory announcements regarding new biosimilar products in Europe and Canada.
centerforbiosimilars3d
Prateek Yadav, MPTh, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars3d
Dan Danielson, RPh, MS
The Top 5 Biosimilar Articles for the Week of December 2 ...